Get Ready for Some Crypto Fun: VolatilityShares Takes a Leap into Solana ETFs!

Welcome to the Wild World of Volatility Shares! Breaking News: Volatility Shares Applies for Solana Futures-Based ETF Hold onto your hats, folks! Volatility Shares, those crafty creators of unique exchange-traded funds (ETFs), have just thrown their hat in the ring for a brand-new offering. That’s right, they’ve submitted an application to the U.S. Securities Exchange…

Read More

“Important Notice for Investors of Sun Communities Inc. from Levi and Korsinsky: A Must-Read for Business and Professional Services Professionals”

Recovering Losses from Sun Communities, Inc.: Understanding Your Rights Introduction As of February 4, 2025, investors who have suffered losses on their Sun Communities, Inc. (NYSE:SUI) investment may have the opportunity to seek recovery under federal securities laws. If you find yourself in this situation, it is important to understand your rights and options. What…

Read More

89bio Secures FDA and EMA Approval for Phase 3 Program in NASH Treatment: Pegozafermin Set to Launch in 2024

89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Alignment on Key Elements of NASH Development Strategy Accelerated Approval Pathway 89bio, a clinical-stage biopharmaceutical company, has announced that they have reached alignment with the FDA and EMA on key elements of their NASH development strategy. One…

Read More

WBTC Purchase of $365M Boosts Total Assets

WLFI’s Latest $9.84 Million wBTC Purchase Highlights Trump Family’s Crypto Holdings The Rise of World Liberty Financial (WLFI) in the Crypto World World Liberty Financial (WLFI) recently made headlines with its significant $9.84 million purchase of Wrapped Bitcoin (wBTC), bringing its total crypto holdings to a staggering $365 million. This move showcases WLFI’s aggressive foray…

Read More

Revolutionizing Cancer Treatment: The Incredible Power of Engeneics’ Nanocell Drug Conjugate for Pancreatic Cancer Patients

EnGeneIC’s breakthrough Armed Nanocell Drug Conjugate (ANDC) treatment shows promising results in Pancreatic cancer SYDNEY and NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) — EnGeneIC, a pioneer in personalised cancer therapeutics, announces the publication of its clinical trial results in peer reviewed prestigious journal “Clinical Cancer Research”, published by the American Association for Cancer Research….

Read More